StockData
BIOANasdaqPharmaceutical PreparationsFiscal year ends December 31

BioAge Labs, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.99+0.15 (+3.10%)

Close on Oct 19, 2026

Market cap
$223.75M
P/E (TTM)
–
Dividend yield
–

SEC filings

27 of BioAge Labs's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KOct 2, 2026Oct 2, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 5, 2026SEC EDGAR
Current report8-KAug 5, 2026Aug 5, 2026SEC EDGAR
Current report8-KJun 10, 2026Jun 12, 2026SEC EDGAR
Current report8-KMay 8, 2026May 8, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 8, 2026SEC EDGAR
Proxy statementDEF 14AJun 10, 2026Apr 21, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 24, 2026SEC EDGAR
Current report8-KMar 24, 2026Mar 24, 2026SEC EDGAR
Current report8-KJan 21, 2026Jan 22, 2026SEC EDGAR
Current report8-KJan 20, 2026Jan 20, 2026SEC EDGAR
Current report8-KJan 12, 2026Jan 12, 2026SEC EDGAR
Current report8-KDec 4, 2025Dec 4, 2025SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 6, 2025SEC EDGAR
Current report8-KNov 6, 2025Nov 6, 2025SEC EDGAR
Quarterly report10-QJun 30, 2025Aug 6, 2025SEC EDGAR
Current report8-KAug 6, 2025Aug 6, 2025SEC EDGAR
Current report8-KJun 5, 2025Jun 9, 2025SEC EDGAR
Current report8-KJun 4, 2025Jun 4, 2025SEC EDGAR
Quarterly report10-QMar 31, 2025May 6, 2025SEC EDGAR
Current report8-KMay 6, 2025May 6, 2025SEC EDGAR
Proxy statementDEF 14AJun 5, 2025Apr 17, 2025SEC EDGAR
Annual report10-KDec 31, 2024Mar 20, 2025SEC EDGAR
Current report8-KMar 20, 2025Mar 20, 2025SEC EDGAR
Quarterly report10-QSep 30, 2024Nov 7, 2024SEC EDGAR
Current report8-KNov 7, 2024Nov 7, 2024SEC EDGAR
Current report8-KSep 25, 2024Sep 27, 2024SEC EDGAR